Veratramine (NSC17821, NSC23880) is an orally active inhibitor of the PI3K/Akt/mTOR signaling pathway and a SIGMAR1 modulator. Veratramine induces autophagic apoptosis of tumor cells, arrests the cell cycle at the G0/G1 phase, and inhibits epithelial-mesenchymal transition (EMT)-related proteins to reduce tumor migration. Veratramine reduces spinal cord and sciatic nerve pathological damage in a neuropathy model by inhibiting SIGMAR1 binding to NMDAR and phosphorylation of NMDAR Ser896. Veratramine has anti-tumor proliferation, apoptosis induction, anti-inflammatory and neuroprotective activities, and can be used in the study of cancers such as liver cancer and osteosarcoma, as well as diabetic peripheral neuropathy[1][2][3][4].
Molecular Weight:
409.60
Purity:
99.84
CAS Number:
[60-70-8]
Formula:
C27H39NO2
Target:
Akt,Apoptosis,Autophagy,mTOR,PI3K
Application Notes:
MCE Product type: Natural Products
* VAT and and shipping costs not included. Errors and price changes excepted
